{"log_id": 2473685700882579780, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.007176, "average": 0.975498, "min": 0.531601}, "location": {"width": 969, "top": 155, "height": 44, "left": 107}, "words": "≥1.5×10°和血小板≥75×10°/时才应该恢复用药。可以重新用之前的剂量(即发生严重"}, {"probability": {"variance": 9e-06, "average": 0.998386, "min": 0.989288}, "location": {"width": 342, "top": 213, "height": 35, "left": 106}, "words": "不良事件之前的剂量)开始给药"}, {"probability": {"variance": 0.000223, "average": 0.992436, "min": 0.925509}, "location": {"width": 595, "top": 259, "height": 39, "left": 107}, "words": " HES/CEL、ASM、 MDS/MPD(起始剂量为400mg/日)"}, {"probability": {"variance": 0.0234, "average": 0.944152, "min": 0.413402}, "location": {"width": 916, "top": 303, "height": 40, "left": 156}, "words": "当中性粒细胞<1.0×10°/L和或血小板<50×10时应停药,在中性粒细胞≥1.5×10/L"}, {"probability": {"variance": 0.007562, "average": 0.979514, "min": 0.494056}, "location": {"width": 969, "top": 351, "height": 42, "left": 109}, "words": "和血小板≥75×10°L时才应该恢复用药,重新治疗剂量400mg/日。如果再次出现危急数值"}, {"probability": {"variance": 0.007367, "average": 0.967284, "min": 0.636591}, "location": {"width": 887, "top": 400, "height": 39, "left": 117}, "words": "(当中性粒细胞<1.0×10°/L和/或血小板<50×10°/),重新治疗剂量应减少至300mg"}, {"probability": {"variance": 0.00116, "average": 0.982307, "min": 0.859674}, "location": {"width": 234, "top": 457, "height": 26, "left": 110}, "words": "DFSP(剂量800mg/日)"}, {"probability": {"variance": 0.012151, "average": 0.955695, "min": 0.462617}, "location": {"width": 917, "top": 494, "height": 39, "left": 158}, "words": "当中性粒细胞<1.0×10°/L和/或血小板<50×10L时应停药,在中性粒细胞≥1.5×10°L"}, {"probability": {"variance": 0.004522, "average": 0.985288, "min": 0.567354}, "location": {"width": 968, "top": 541, "height": 43, "left": 110}, "words": "和血小板≥75×10°/时才应该恢复用药,重新治疗剂量600mg/日。如果再次出现危急数值"}, {"probability": {"variance": 0.003294, "average": 0.982447, "min": 0.644181}, "location": {"width": 880, "top": 593, "height": 37, "left": 119}, "words": "(当中性粒细胞<1.0×10°/L和/或血小板<50×10L),重新治疗剂量应减少至400mg"}, {"probability": {"variance": 1e-06, "average": 0.999429, "min": 0.997341}, "location": {"width": 249, "top": 646, "height": 33, "left": 108}, "words": "肝功能损害患者的剂量"}, {"probability": {"variance": 0.000194, "average": 0.995847, "min": 0.912803}, "location": {"width": 919, "top": 685, "height": 41, "left": 159}, "words": "轻、中度肝功能损害者推荐使用最小剂量400mg/天。目前尚无严重肝功能损害患者(胆"}, {"probability": {"variance": 2.4e-05, "average": 0.998021, "min": 0.970382}, "location": {"width": 972, "top": 732, "height": 43, "left": 108}, "words": "红素>正常范围的3倍)使用剂量为400mg天的数据资料。这些患者应在认真权衡风险评估"}, {"probability": {"variance": 3e-06, "average": 0.998915, "min": 0.994583}, "location": {"width": 169, "top": 792, "height": 28, "left": 111}, "words": "后,再使用本品"}, {"probability": {"variance": 0, "average": 0.999326, "min": 0.997988}, "location": {"width": 248, "top": 837, "height": 35, "left": 111}, "words": "肾功能衰竭患者的剂量"}, {"probability": {"variance": 4e-06, "average": 0.999053, "min": 0.989569}, "location": {"width": 920, "top": 877, "height": 42, "left": 161}, "words": "伊马替尼的肾清除可以忽略。由于这个原因,预计对肾功能损害患者的全身清除率没有"}, {"probability": {"variance": 2e-06, "average": 0.99921, "min": 0.993798}, "location": {"width": 558, "top": 929, "height": 40, "left": 114}, "words": "减少。然而,对严重肾功能损害的患者仍需特别注意"}, {"probability": {"variance": 0, "average": 0.999053, "min": 0.998148}, "location": {"width": 171, "top": 984, "height": 31, "left": 116}, "words": "老年患者的剂量"}, {"probability": {"variance": 0, "average": 0.97272, "min": 0.97272}, "location": {"width": 183, "top": 957, "height": 94, "left": 703}, "words": " PHARMACEUTICAL"}, {"probability": {"variance": 3e-06, "average": 0.998446, "min": 0.994757}, "location": {"width": 341, "top": 1030, "height": 30, "left": 163}, "words": "对老年患者没有特别的调整剂量"}, {"probability": {"variance": 0, "average": 0.999725, "min": 0.999304}, "location": {"width": 130, "top": 1080, "height": 29, "left": 123}, "words": "【不良反应】"}, {"probability": {"variance": 0, "average": 0.999747, "min": 0.999587}, "location": {"width": 123, "top": 1130, "height": 28, "left": 116}, "words": "安全性总结"}, {"probability": {"variance": 0.002523, "average": 0.99108, "min": 0.685618}, "location": {"width": 921, "top": 1165, "height": 42, "left": 164}, "words": "伊马替尼在人体临床使用中的总体安全性特征通过伊马替尼超过12年的使用经验进行"}, {"probability": {"variance": 0, "average": 0.957534, "min": 0.957534}, "location": {"width": 65, "top": 1106, "height": 98, "left": 1150}, "words": "("}, {"probability": {"variance": 3e-06, "average": 0.998956, "min": 0.992315}, "location": {"width": 967, "top": 1211, "height": 46, "left": 118}, "words": "了总结描述。在临床开发中,大多数患者在治疗的某一时间点会发生不良事件。最常报告的"}, {"probability": {"variance": 0.000145, "average": 0.995858, "min": 0.923299}, "location": {"width": 955, "top": 1260, "height": 44, "left": 119}, "words": "不良事件(>10%)为中性粒细胞减少,血小板减少,贫血,头痛,消化不良,水肿,体重增加"}, {"probability": {"variance": 2e-06, "average": 0.999284, "min": 0.994427}, "location": {"width": 968, "top": 1308, "height": 43, "left": 118}, "words": "恶心,呕吐,肌肉痉挛,肌肉骨骼痛,腹泻,皮疹,疲劳和腹痛。这些事件的严重程度均为"}, {"probability": {"variance": 1e-06, "average": 0.999399, "min": 0.995619}, "location": {"width": 891, "top": 1357, "height": 43, "left": 120}, "words": "轻度至中度,且只有2%~5%的患者因发生药物相关性不良事件导致治疗永久性终止"}, {"probability": {"variance": 3.6e-05, "average": 0.996823, "min": 0.974051}, "location": {"width": 921, "top": 1404, "height": 43, "left": 166}, "words": "在Ph+白血病和实体肿瘤患者间的安全性差异是在Ph+白血病患者中发生骨髓抑制以及"}, {"probability": {"variance": 1.9e-05, "average": 0.998163, "min": 0.982185}, "location": {"width": 970, "top": 1452, "height": 44, "left": 119}, "words": "在GIST患者中发生GI和肿瘤内出血的发病率和严重程度较高,并且很可能是由于疾病相关"}, {"probability": {"variance": 5.1e-05, "average": 0.996903, "min": 0.959115}, "location": {"width": 971, "top": 1499, "height": 44, "left": 119}, "words": "的因素造成的。骨髓抑制,GI不良事件,水肿和皮疹是这两个患者群所常见的。其他GI情"}], "language": 3}